November 18, 2025 — Leads & Copy — OmniAb, Inc. and ArrowMark Partners have entered into a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors.
Under the agreement, OmniAb (NASDAQ: OABI) will receive revenue for services performed. The company is also eligible for potential equity and royalties tied to the discovery of novel antibodies for targets defined by Mabtrx.
Matt Foehr, President and Chief Executive Officer of OmniAb, said the company is pleased to engage with ArrowMark and Viking and their latest NewCo as its newest technology and discovery services partner. Foehr added that ArrowMark and Viking have a history of successful biotech investments, high-science analysis and value creation.
Foehr also stated that the transaction highlights how OmniAb can leverage its novel transgenic chicken-based technologies to deliver value through multiple innovative strategies across different time horizons.
Tony Yao, M.D., Ph.D., Life Science Portfolio Manager for ArrowMark, said the company believes that some of the most important and valuable next-generation drug targets can be addressed by leveraging OmniAb’s novel suite of technologies and services.
ArrowMark Partners, founded in 2007 and based in Denver, Colorado, is an employee-owned investment management firm. The firm focuses on niche and less efficient market segments in public and private credit and equity, leveraged loans and middle-market commercial real estate finance.
Viking Global Investors L.P., founded in 1999, is a global investment firm managing over $55 billion of capital across public and private investments. Viking has offices in Stamford, New York, Hong Kong, London, and San Francisco, and is registered as an investment adviser with the U.S. Securities and Exchange Commission. For more information, please visit www.vikingglobal.com.
OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. The OmniAb platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for drug development efforts. At the heart of the OmniAb platform is Biological Intelligence™, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions that the press release contains forward-looking statements. These statements are based on current beliefs and expectations and are subject to risks and uncertainties.
These statements include expectations regarding a continued collaboration between OmniAb and JV for other drug discovery efforts with future NewCos, the realization of potential economics in the form of royalties and/or revenue share on future product sales, and whether OmniAb-derived antibodies have the potential to form the basis of innovative standalone biotech companies.
Actual results may differ due to risks and uncertainties inherent in OmniAb’s business, including acceptance of OmniAb’s technology, the eventual development of products by OmniAb’s partners, changes in technology, uncertainties regarding the value of OmniAb’s Mabtrx warrant, and the absence of any contractual assurance that future NewCos would enter into favorable agreements with OmniAb.
The company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date of the release.
Source: OmniAb
